← All trials
NCT05548283
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2023
- Primary completion
- Nov 15, 2026
- Completion date
- Nov 15, 2026
- First posted
- Sep 21, 2022
- Last posted
- Sep 21, 2022
- Enrollment
- 730
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonCollaborator
- University of WashingtonSponsor investigator
- Medical University of South CarolinaCollaborator
- Medical University of South CarolinaOverall official - principal investigator
- Cystic Fibrosis FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.